Biogen Rides the Spinraza Wave to Double-Digit Growth

Biogen (NASDAQ:BIIB) put up solid double-digit revenue growth in the second quarter, with earnings growing even faster. But investors rightfully continue to worry about the future when year-over-year comparisons for its current growth driver, recently launched Spinraza, start to get tougher.